Exendin-4 (Ex-4), a glucagon-like peptide 1-receptor (GLP-1R) agonist, approved for adult type 2 diabetes treatment, has been shown to be protective towards BBB integrity by inhibiting MMP-9 in a rat model of ischemic stroke [83]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.